Physicians from MD Anderson Cancer Center in Houston, Texas, recently published an analysis to determine the frequency of carcinoid syndrome in patients with neuroendocrine tumors.
According to the authors, the frequency of carcinoid syndrome in NET patients has not been systematically assessed previously.
The study, published in the April 2017 issue of The Lancet examined NET cases from the National Cancer Institute’s SEER (Surveillance, Epidemiology and End Results project) database from April 2000 to December 2011.
Of 9,512 cases during this time period, 1,786 or 19 percent of patients experienced carcinoid syndrome. The number of patients diagnosed with carcinoid syndrome increased over this time period from 50 (11%) of 465 patients in 2000 to 160 (19%) of 854 in 2011.
There were slightly more women affected than men, and overall survival of carcinoid syndrome patients was less than NET patients without carcinoid syndrome—five years versus 5.6 years. Race and ethnicity also played a role.